Promontory Therapeutics to Present Research on PT-112 in Advanced Non-Small Cell Lung Cancer at the ESMO Immuno-Oncology Congress 2022
Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.
- Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.
- Abstracts will also be published online in the ESMO-IO Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).
- PT-112 represents a highly potent inducer of this immunological form of cancer cell death.
- Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.